PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 Please type a plus sign (+) inside this box --> + U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 5 2004 Upder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/680,905 **TRANSMITTAL** October 7, 2003 Filing Date **FORM First Named Inventor** Stephen D. Pacetti (to be used for all correspondence after initial filing) **Group Art Unit** 1762 Unassigned **Examiner Name** Total Number of Pages in This Submission 11 **Attorney Docket Number** 50623.243 (excluding references) ENCLOSURES (check all that apply) Deposit Account 07-1850 After Allowance Communication to **Assignment Papers** Authorization (for an Application) Group Drawing(s) In/Formal Sheets with Appeal Communication to Board of Fee Attached Appeals and Interferences Submission of Drawings Transmittal Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Status Letter Affidavits/declaration(s) **Provisional Application** Power of Attorney, Revocation Other Enclosure(s) Postage Paid Postcard Change of Correspondence Address (please identify below): Terminal Disclaimer with Form PTO-1449 and \_\_\_\_\_208\_\_ Request for Refund References Request for Corrected Notice of CD, Number of CD(s)\_ Recordation Recordation Form Cover Sheet Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Squire, Sanders & Dempsey L.L.P. Paul J. Meyer, Jr., Reg. No. 47,791 Individual name Signature February 2004 Date CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: Februar<sub>4</sub> Dilora Haddad Typed or printed name

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

February 0

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reApplication of:

Examiner: Unassigned

Stephen D. Pacetti et al.

Serial No.:

10/680,905

Art Unit: 1762

Filed:

October 7, 2003

Title:

System and Method for Coating a Tubular Implantable Medical Device

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

## Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §\$1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. One copy of the cited references is submitted herewith. The Examiner is requested to make this information of official record in the application.

The submission of the listed documents is not intended as an admission that any such documents constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R.

§1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: February 2,2004

Facsimile (415) 393-9887

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Respectfully submitted,

Paul J\Meyer, Jr.

Attorney for Applicants

Reg. No. 47,791

FORM PTO-1449 (Modified)

US DEPARTMENT OF COMMERCE | Docket No.

Apprever posuse through 10/31/2002

US Patent and Trademark Office

50623.243

Application No. 10/680,905

INFORMATION DISCLOSURE CITATION in an Application

Applicant

Stephen D. Pacetti et al.

FEB 0 5 2004 (Use several sheets if necessary)

Filing Date

Group Art Unit

October 7, 2003

1762

<u>g</u>	<i>&amp;y</i>	October 7, 2003 1762					
Examiner	Chi.		U.S. PATI		· · · · ·		
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,329,383	5/11/82	Joh	428	36	
	A2	4,733,665	3/29/88	Palmaz	128	343	
	А3	4,800,882	1/31/89	Gianturco	128	343	-
	A4	4,882,168	11/21/89	Casey et al.	424	468	
	A5	4,886,062	12/12/89	Wiktor	128	343	
	A6	4,941,870	7/17/90	Okada et al.	600	36	
	A7	4,977;901	12/18/90	Ofstead	128	772	
	A8	5,112,457	5/12/92	Marchant	204	165	
•.	A9	5,165,919	11/24/92	Sasaki et al.	424	488	
	A10	5,272,012	12/21/93	Opolski	428	423.1	
	A11	5,292,516	3/8/94	Viegas et al.	424	423	
	A12	5,298,260	3/29/94	Viegas et al.	424	486	
	A13	5,300,295	4/5/94	Viegas et al.	424	427	
	A14	5,306,501	4/26/94	Viegas et al.	424	423	
	A15	5,328,471	7/12/94	Slepian	604	101	
	A16	5,330,768	7/19/94	Park et al.	424	501	
	A17	5,380,299	1/10/95	Fearnot et al.	604	265	
	A18	5,417,981	5/23/95	Endo et al.	424	486	
	A19	5,447,724	9/5/95	Helmus et al.	424	426	
	A20	5,455,040	10/3/95	Marchant	424	426	
	A21	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	A22	5,464,650	11/7/95	Berg et al.	427	2.30	
·	A23	5,569,463	10/29/96	Helmus et al.	424	426	
	A24	5,578,073	11/26/96	Haimovich et al.	623	1	
	A25	5,605,696	2/25/97	Eury et al.	424	423	
	A26	5,609,629	3/11/97	Fearnot et al.	623	1	

FFR 0 5 on 5	•	<b>~</b>			· · · · · · · · · · · · · · · · · · ·	
A27	5,624,411	4/29/97	Tuch	604	265	
RADEN A 28	5,628,730	5/13/97	Shapland et al.	604	21	
A29	5,649,977	7/22/97	Campbell	623	1	
A30	5,658,995	8/19/97	Kohn et al.	525	432	
A31	5,667,767	9/16/97	Greff et al.	424	9.411	
A32	5,670,558	9/23/97	Onishi et al.	523	112	
A33	5,679,400	10/21/97	Tuch	427	2.14	
A34	5,700,286	12/23/97	Tartaglia et al.	623	1	
A35	5,702,754	12/30/97	Zhong	427	2.12	
A36	5,716,981	2/10/98	Hunter et al.	514	449	
A37	5,735,897	4/7/98	Buirge	623	12	
A38	5,746,998	5/5/98	Torchilin et al.	424	9.4	
A39	5,776,184	7/7/98	Tuch	623	1	
A40	5,788,979	8/4/98	Alt et al.	424	426	<del></del>
A41	5,800,392	9/1/98	Racchini	604	96	
A42	5,820,917	10/13/98	Tuch	427	2.1	
A43	5,824,048	10/20/98	Tuch	623	1	
A44	5,824,049	10/20/98	Ragheb et al.	623	1	
A45	5,830,178	11/3/98	Jones et al.	604	49	
A46	5,837,008	11/17/98	Berg et al.	623	1	
A47	5,837,313	11/17/98	Ding et al.	427	2.21	
A48	5,851,508	12/22/98	Greff et al.	424	9.411	
A49	5,858,746	1/12/99	Hubbell et al.	435	177	
A50	5,865,814	2/2/99	Tuch	604	265	
A51	5,869,127	2/9/99	Zhong	427	2.12	
A52	5,873,904	2/23/99	Ragheb et al.	623	1	
A53	5,876,433	3/2/99	Lunn	623	1	
A54	5,877,224	3/2/99	Brocchini et al.	514	772.2	: 
A55	5,925,720	7/20/99	Kataoka et al.	525	523	
A56	5,955,509	9/21/99	Webber et al.	514	772.7	<del></del> -
A57	5,971,954	10/26/99	Conway et al.	604	96	
A58	5,980,928	11/9/99	Terry	424	427	

FEB (	5 2004					•	
	A59 A A60 A61	5,980,972	11/9/99	Ding	427	2.24	
E TRAI	2EN460	5,997,517	12/7/99	Whitbourne	604	265	
	A61	6,010,530	1/4/00	Goicoechea	623	1	
	A62	6,015,541	1/18/00	Greff et al.	424	1.25	
<del></del>	A63	6,033,582	3/7/00	Lee et al.	216	37	
	A64	6,042,875	3/28/00	Ding et al.	427	2.24	
	A65	6,051,648	4/18/00	Rhee et al.	525	54.1	
	A66	6,051,576	4/18/00	Ashton et al.	514	255	
	A67	6,056,993	5/2/00	Leidner et al.	427	2.25	
	A68	6,060,451	5/9/00	DiMaio et al.	514	13	
	A69	6,060,518	5/9/00	Kabanov et al.	514	781	
	A70	6,080,488	6/27/00	Hostettler et al.	428	423.3	
	A71	6,096,070	8/1/00	Ragheb et al.	623	1	
	A72	6,099,562	8/8/00	Ding et al.	623	1.46	
	A73	6,110,188	8/29/00	Narciso, Jr.	606	153	
	A74	6,110,483	8/29/00	Whitbourne et al.	424	423	
	A75	6,113,629	9/5/00	Ken	623	1.1	
	A76	6,120,536	9/19/00	Ding et al.	623	1.43	
	A77	6,120,904	9/19/00	Hostettler et al.	428	423.3	
	A78	6,121,027	9/19/00	Clapper et al.	435	180	
	A79	6,129,761	10/10/00	Hubbell	623	11	
	A80	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A81	6,165,212	12/26/00	Dereume et al.	623	1.13	,
	A82	6,203,551	3/20/01	Wu	606	108	
	A83	6,231,600	5/15/01	Zhong	623	1.42	
	A84	6,240,616	6/5/01	Yan	29	527.2	
	A85	6,245,753	6/12/01	Byun et al.	514	56	
	A86	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	
	A87	6,254,632	7/3/01	Wu et al.	623	1.15	
	A88	6,258,121	7/10/01	Yang et al.	623	1.46	
	A89	6,283,947	9/4/01	Mirzaee	604	264	-

<u> </u>	A90	6,283,949	9/4/01	Roorda	604	288.02	
	A91	6,284,305	9/4/01	Ding et al.	427	2.28	
	A92	6,287,628	9/11/01	Hossainy et al.	427	2.3	
				-		265	
	A93 A94	6,299,604 6,306,176	10/9/01	Ragheb et al. Whitbourne	604	23.59	
	A95	6,331,313	12/18/01	Wong et al.	424	427	
	A96	6,335,029	1/1/02	Kamath et al.	424	423	
	A97	6,346,110	2/12/02	Wu	606	108	
	A98	6,358,556	3/19/02	Ding et al.	427	2.24	
	A99	6,379,381	4/30/02	Hossainy et al.	623	1.42	
	A100	6,395,326	5/28/02	Castro et al.	427	2.24	
- <b>A</b>	A101	6,419,692	7/16/02	Yang et al.	623	1.15	
	A102	6,451,373	9/17/02	Hossainy et al.	427	2.25	
	A103	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A104	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A105	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A106	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A107	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A108	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A109	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A110	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A111	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A112	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A113	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A114	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
١	A115	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A116	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A117	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A118	6,585,926	7/1/03	Mirzaee	264	400	8/31/00

FEB 0	A119	6,605,154	8/12/03	Villareal	118	500	5/3	1/01
TRADE	MACH		NT APPLICAT	ION PUBLICATION DOC	UMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Appro	
	A120	2001/0018469	8/30/01	Chen et al.	523	121		
	A121	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15		
	A122	2002/0077693	6/20/02	Barclay et al.	623	1.13		
	A123	2002/0091433	7/11/02	Ding et al.	623	1.2		
	A124	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	/01
	A125	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	)/02
	A126	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS				
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
	B1	EP 0 301 856	2/1/89	European				
	B2	EP 0 514 406	11/25/92	European				
	В3	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European				
	B5	EP 0 665 023	8/2/95	European				
	B6	EP 0 701 802	3/20/96	European				
	B7	EP 0 716 836	6/19/96	European				
	B8	EP 0 809 999	12/3/97	European				
	В9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European				
	B11	EP 0 879 595	11/25/98	European				
	B12	EP 0 910 584	4/28/99	European				
	B13	EP 0 923 953	6/23/99	European	,			
	B14	EP 0 953 320	11/3/99	European				
	B15	EP 0 970 711	1/12/00	European				
	B16	EP 0 982 041	3/1/00	European				
	B17	EP 1 273 314	1/8/03	European			•	
	B18	2001-190687	7/17/01	Japan (Abstract)			Х	
	B19	WO 91/12846	9/5/91	PCT				
•	B20	WO 95/10989	4/27/95	PCT				

B214	WO 96/40174	12/19/96	PCT				1
B214 B22	VVO 90/401/4					<del> </del>	-
B22	WO 97/10011	3/20/97	PCT	_			-
B23	WO 97/45105	12/4/97	PCT				
B24	WO 97/46590	12/11/97	PCT				
B25	WO 98/17331	4/30/98	PCT				
B26	WO 98/36784	8/27/98	PCT				
B27	WO 99/01118	1/14/99	PCT				
B28	WO 99/38546	8/5/99	PCT				
B29	WO 99/63981	12/16/99	PCT			·	
B30	WO 00/02599	1/20/00	PCT				
B31	WO 00/12147	3/9/00	PCT				
B32	WO 00/18446	4/6/00	PCT				L
B33	. WO 00/64506	11/2/00	PCT				
B34	WO 01/01890	1/11/01	PCT				
B35	WO 01/15751	3/8/01	PCT				
B36	WO 01/17577	3/15/01	PCT				
B37	WO 01/45763	6/28/01	PCT				
B38	WO 01/49338	7/12/01	PCT				
B39	WO 01/74414	10/11/01	PCT				
B40	WO 02/03890	1/17/02	PCT				
B41	WO 02/026162	4/4/02	PCT				
B42	WO 02/34311	5/2/02	PCT				
B43	WO 02/056790	7/25/02	PCT				
B44	WO 03/000308	1/3/03	PCT				
B45	WO 03/022323	3/20/03	PCT				
B46	WO 03/028780	4/10/03	PCT				
B47	WO 03/037223	5/8/03	PCT				
B48	WO 03/039612	5/15/03	PCT <sup>-</sup>				
· · · · · · · · · · · · · · · · · · ·	OTHER DO	CUMENTS (Incli	uding Author, Title, Date, Pertinent P	ages, etc.)			
C1			ne Dream Stent, Clinica 710:15 (J t?req=1061848202959, printed 8				
C2	Anonymous, <i>Heparin</i> -http://www.dialogweb	-coated stents cut	complications by 30%, Clinica 73	2:17 (Nov.	18, 1996	 6),	

/	ζ.	Page 7 of 8
FEB 0'5	2004	<u>.</u>
FEB 0.5	C3 6	Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
RADE	C4	Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?reg=1061848017752, printed 8/25/03 (2 pages).
		Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
		Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).
		Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Coating Techniques, Air Knife Coating, <a href="http://www.ferron-magnetic.co.uk/coatings/airknife.htm">http://www.ferron-magnetic.co.uk/coatings/airknife.htm</a> , 1 page, printed 07/01/03.
		Coating Techniques, Gravure Coating, <a href="http://www.ferron-magnetic.co.uk/coatings/gravure.htm">http://www.ferron-magnetic.co.uk/coatings/gravure.htm</a> , 2 pages, printed 07/01/03.
	C10	Coating Techniques, Reverse Roll Coating, <a href="http://www.ferron-magnetic.co.uk/coatings/revroll.htm">http://www.ferron-magnetic.co.uk/coatings/revroll.htm</a> , 2 pages, printed 07/01/03.
•		Coating Techniques, Gap Coating, <a href="http://www.ferron-magnetic.co.uk/coatings/knife.htm">http://www.ferron-magnetic.co.uk/coatings/knife.htm</a> , 1 page, printed 07/01/03.
	C12	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).
,		Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
		Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).
		Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).
	C16	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).
		Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).
		Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
		Kataoka et al., <i>Block copolymer micelles as vehicles for drug deliver</i> y, Journal of Controlled Release 24:119-132 (1993).
		Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
		Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
		Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
		Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
		Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing</i> Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
		Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).

/	<b>6</b> ,	1 19	E	6	è,
PA	FEB	0 5	5 2	004	4
A.				26	K.

· <b>B</b>							
E A TRACT	C26,	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p 321 (P1694), Abstr. Suppl. (1993).					
	C27	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).					
	C28	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).					
	C29	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).					
	C30	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).					
	C31	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).					
	C32	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).					
	C33	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).					
•	C34	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).					
EXAMINER		DATE CONSIDERED					

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.